3 results
Approved WMOCompleted
Primary Objective: Evaluation of the potential of the incorporated SFR spectroscopy into the EUS-FNA procedure to discriminate benign and malignant pancreas tissue in vivo.Secondary Objective: To measure the wavelength dependent differences in…
Not approvedWill not start
To better understand the utilities of the new BETACONNECT device and characterize its contribution to adherence, we plan to prospectively follow-up MS patients using the device for 24 weeks.
Approved WMORecruiting
Primary Objective: - The ability of SFR spectroscopy incorporated in EUS-FNA procedure in distinguishing benign and malignant pancreatic tissue by measuring wavelength dependent optical characteristics over a broad wavelength range (400-1000 nm).…